Rates of adverse and serious adverse events in children with cystic fibrosis
- 18 March 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (6), 972-977
- https://doi.org/10.1016/j.jcf.2021.02.013
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
- Cystic Fibrosis Research Foundation (LAGUNA16Y5, PITTMA16Y5, SANDERS16Y5)
This publication has 15 references indexed in Scilit:
- Prevention of cystic fibrosis: The beginning of the end?Science Translational Medicine, 2019
- Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyThe Lancet Respiratory Medicine, 2018
- Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based StudyClinical Infectious Diseases, 2017
- Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort studyJournal of Cystic Fibrosis, 2015
- Progress in cystic fibrosis and the CF Therapeutics Development NetworkThorax, 2012
- Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic FibrosisArchives of Pediatrics & Adolescent Medicine, 2011
- Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosaA Randomized Controlled TrialJAMA, 2010
- Cystic fibrosisThe Lancet, 2009
- Laboratory parameter profiles among patients with cystic fibrosisJournal of Cystic Fibrosis, 2007
- Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trialsContemporary Clinical Trials, 2006